Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.06038.x · Cited by 2,078 · see citing works

Non-Transgenic Mouse Models of Kidney Disease

Rabe, M., & Schaefer, F. S. (2016) · ˜The œNephron journals/Nephron journals · doi:10.1159/000445171 · Cited by 1,925 · see citing works

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748 · see citing works

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Shah, A. G., Lydecker, A. D., Murray, K. F., Tetri, B., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,561 · see citing works

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E. A., Anstee, Q. M., Sheridan, D. A., Guha, I. N., Cobbold, J., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,425 · see citing works

From NASH to HCC: current concepts and future challenges

Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · see citing works

Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ

Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251 · see citing works

Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis

Feldstein, A. E., Wieckowska, A., López, R., Liu, Y., Zein, N. N., & McCullough, A. J. (2009) · Hepatology · doi:10.1002/hep.23050 · Cited by 711 · see citing works

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

Bédossa, P. (2014) · Hepatology · doi:10.1002/hep.27173 · Cited by 624 · see citing works

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers

Vilar‐Gómez, E., & Chalasani, N. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 608 · see citing works

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549 · see citing works

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538 · see citing works

An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitis

Matsumoto, M., Hada, N., Sakamaki, Y., Uno, A., Shiga, T., Tanaka, C., Ito, T., Katsume, A., & Sudoh, M. (2013) · International Journal of Experimental Pathology · doi:10.1111/iep.12008 · Cited by 523 · see citing works

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479 · see citing works

NAFLD as a driver of chronic kidney disease

Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449 · see citing works

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

Caussy, C., Alquiraish, M. H., Nguyen, P., Hernandez, C., Cepin, S., Fortney, L., Ajmera, V. H., Bettencourt, R., Collier, S., Hooker, J. C., et al. (2017) · Hepatology · doi:10.1002/hep.29639 · Cited by 378 · see citing works

Liver biopsy: The best, not the gold standard

Bédossa, P., & Carrat, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.014 · Cited by 349 · see citing works

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347 · see citing works

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples

Veldman-Jones, M. H., Brant, R., Rooney, C., Geh, C., Emery, H., Harbron, C. G., Wappett, M., Sharpe, A. D., Dymond, M., Barrett, J. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0262 · Cited by 330 · see citing works

Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children

Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303 · see citing works

Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions

Kennedy, P., Wagner, M., Castéra, L., Hong, C. W., Johnson, C. L., Sirlin, C. B., & Taouli, B. A. (2018) · Radiology · doi:10.1148/radiol.2018170601 · Cited by 271 · see citing works

What is the future of PEGylated therapies?

Swierczewska, M., Lee, K. C., & Lee, S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1113254 · Cited by 249 · see citing works

BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy

Hudkins, K. L., Pichaiwong, W., Wietecha, T., Kowalewska, J., Banas, M. C., Spencer, M. W., Mühlfeld, A., Koelling, M., Pippin, J. W., Shankland, S. J., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121290 · Cited by 228 · see citing works

Matrix metalloproteinases and liver fibrosis (translational aspects)

Roeb, E. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.12.012 · Cited by 216 · see citing works

Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.

Kwong, G. A., von Maltzahn, G., Murugappan, G., et al. (2013) · PubMed · doi:10.1038/nbt.2464 · Cited by 213 · see citing works

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Siddiqui, M. S., Harrison, S. A., Abdelmalek, M. F., Anstee, Q. M., Bédossa, P., Castéra, L., Dimick‐Santos, L., Friedman, S. L., Greene, K., Kleiner, D. E., et al. (2017) · Hepatology · doi:10.1002/hep.29607 · Cited by 167 · see citing works

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

Alkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668374 · Cited by 162 · see citing works

Suppressed mitochondrial biogenesis in folic acid-induced acute kidney injury and early fibrosis

Stallons, L. J., Whitaker, R. M., & Schnellmann, R. G. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.11.014 · Cited by 141 · see citing works

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease

Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140 · see citing works

Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis

Han, M. A. T., Altayar, O., Hamdeh, S., Takyar, V. K., Rotman, Y., Etzion, O., Lefebvre, E. A., Safadi, R., Ratziu, V., Prokop, L. J., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.011 · Cited by 135 · see citing works

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

Drescher, H. K., Weiskirchen, S., & Weiskirchen, R. (2019) · Cells · doi:10.3390/cells8080845 · Cited by 134 · see citing works

Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease

Helsley, R. N., Varadharajan, V., Brown, A. L., Gromovsky, A. D., Schugar, R. C., Ramachandiran, I., Fung, K., Kabbany, M. N., Banerjee, R., Neumann, C. K. A., et al. (2019) · eLife · doi:10.7554/elife.49882 · Cited by 132 · see citing works

Non-invasive early detection of acute transplant rejection via nanosensors of granzyme B activity

Mac, Q. D., Mathews, D., Kahla, J. A., Stoffers, C. M., Delmas, O. M., Holt, B. A., Adams, A. B., & Kwong, G. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0358-7 · Cited by 120 · see citing works

Acute Kidney Injury in Patients with Cirrhosis

Russ, K. B., Stevens, T. M., & Singal, A. K. (2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00015 · Cited by 118 · see citing works

Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential #

Moles, A., Tarrats, N., Fernández-Checa, J. C., & Marı́, M. (2008) · Hepatology · doi:10.1002/hep.22753 · Cited by 105 · see citing works

Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis

Ryaboshapkina, M., & Hammar, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10930-w · Cited by 98 · see citing works

Practice patterns in NAFLD and NASH: real life differs from published guidelines

Rinella, M. E., Lominadze, Z., Loomba, R. S., Charlton, M., Neuschwander‐Tetri, B. A., Caldwell, S. H., Kowdley, K. V., & Harrison, S. A. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15611581 · Cited by 95 · see citing works

Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling

Kirkpatrick, J. D., Warren, A., Soleimany, A. P., Westcott, P. M. K., Voog, J. C., Martin-Alonso, C., Fleming, H. E., Tammela, T., Jacks, T., & Bhatia, S. N. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0262 · Cited by 95 · see citing works

Fibroblast activation protein (FAP) as a novel metabolic target

Sanchez-Garrido, M. A., Habegger, K. M., Clemmensen, C., Holleman, C. L., Müller, T. D., Pérez–Tilve, D., Li, P., Agrawal, A., Finan, B., Drucker, D. J., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.07.003 · Cited by 79 · see citing works

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic.

Pandyarajan, V., Gish, R. G., Alkhouri, N., & Noureddin, M. (2019) · PubMed Central · Cited by 78 · see citing works

Comorbidities and Metabolic Derangement of NAFLD

Bang, K. B., & Cho, Y. K. (2015) · Journal of Lifestyle Medicine · doi:10.15280/jlm.2015.5.1.7 · Cited by 76 · see citing works

Classification of prostate cancer using a protease activity nanosensor library

Dudani, J. S., Ibrahim, M., Kirkpatrick, J. D., Warren, A., & Bhatia, S. N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805337115 · Cited by 69 · see citing works

Cathepsin D regulates lipid metabolism in murine steatohepatitis

Houben, T., Oligschlaeger, Y., Hendrikx, T., Bitorina, A. V., Walenbergh, S. M. A., van Gorp, P. J., Gijbels, M. J., Friedrichs, S., Plat, J., Schaap, F. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03796-5 · Cited by 66 · see citing works

The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling

Uchimura, K., Hayata, M., Mizumoto, T., Miyasato, Y., Kakizoe, Y., Morinaga, J., Onoue, T., Yamazoe, R., Ueda, M. U., Adachi, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms4428 · Cited by 59 · see citing works

Mathematical framework for activity-based cancer biomarkers

Kwong, G. A., Dudani, J. S., Carrodeguas, E., Mazumdar, E., Zekavat, S. M., & Bhatia, S. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506925112 · Cited by 51 · see citing works

Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention

Walenbergh, S. M. A., Houben, T., Rensen, S. S., Bieghs, V., Hendrikx, T., van Gorp, P. J., Oligschlaeger, Y., Jeurissen, M. L. J., Gijbels, M. J., Buurman, W. A., et al. (2016) · Scientific Reports · doi:10.1038/srep38278 · Cited by 44 · see citing works

Technology evaluation: A critical step in the clinical utilization of novel diagnostic tests for liver fibrosis

Afdhal, N. H., & Curry, M. P. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.008 · Cited by 43 · see citing works

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis

Ando, W., Yokomori, H., Tsutsui, N., Yamanouchi, E., Suzuki, Y., Oda, M., Inagaki, Y., Otori, K., & Okazaki, I. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0030 · Cited by 43 · see citing works

Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance

Toonen, E. J. M., Mirea, A.-M., Tack, C. J., Stienstra, R., Ballak, D. B., van Diepen, J. A., Hijmans, A., Chavakis, T., Dokter, W. H. A., Pham, C. T. N., et al. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00033 · Cited by 40 · see citing works

Proteases Revisited: Roles and Therapeutic Implications in Fibrosis

Kryczka, J. M., & Boncela, J. (2017) · Mediators of Inflammation · doi:10.1155/2017/2570154 · Cited by 37 · see citing works

Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers

Irvine, K. M., Wockner, L. F., Hoffmann, I., Horsfall, L. U., Fagan, K. J., Bijin, V. A., Lee, B. T. K., Clouston, A. D., Lampe, G., Connolly, J. E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167001 · Cited by 36 · see citing works

Differential expression of matrix metalloproteinases in viral and non-viral chronic liver diseases

Ljumovic, D., Diamantis, I. D., Alegakis, A. K., & Kouroumalis, E. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.06.028 · Cited by 31 · see citing works

Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection

D’Amico, F., Consolo, M., Amoroso, A., Skarmoutsou, E., Mauceri, B., Stivala, F., Malaponte, G., Bertino, G., Neri, S., & Mazzarino, M. C. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2009.05.005 · Cited by 30 · see citing works

Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases

Toyoda, H., Kumada, T., Kiriyama, S., et al. (2012) · Biomarkers · doi:10.3109/1354750x.2012.738249 · Cited by 29 · see citing works

Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Wong, T., Wong, R. J., & Gish, R. G. (2019) · Europe PMC (PubMed Central) · Cited by 29 · see citing works

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD

Dibba, P., Li, A. A., Perumpail, B. J., John, N., Sallam, S., Shah, N. D., Kwong, W., Cholankeril, G. T., Kim, D., & Ahmed, A. (2018) · Diseases · doi:10.3390/diseases6030083 · Cited by 27 · see citing works

The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy

Ericsson, A., Tonelius, P., Lal, M., Sabirsh, A., Böttcher, G., William‐Olsson, L., Strömstedt, M., Johansson, C., Hyberg, G., Tapani, S., et al. (2017) · Physiological Reports · doi:10.14814/phy2.13186 · Cited by 16 · see citing works

Non-biopsy methods to determine hepatic fibrosis.

Fierbinteanu-Braticevici, C. G., & Purcarea, M. R. (2010) · PubMed · Cited by 11 · see citing works

Combination of an FXR agonist and an ACC inhibitor increases anti-fibrotic efficacy in rodent models of NASH

Bates, J., Hollenback, D., Zagórska, A., et al. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)31026-2 · Cited by 2 · see citing works

Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430 · see citing works

Impact of non-invasive biomarkers on hepatology practice: past, present and future

Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224 · see citing works

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158 · see citing works

Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease

Chalasani, N., Wilson, L., Kleiner, D. E., Cummings, O. W., Brunt, E. M., & Ünalp, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.016 · Cited by 251 · see citing works

STUDY OF CELL MODELS OF HEPG2 STEATOSIS AND STEATOHEPATITIS VIABILITY

Шунькина, Д. А., Дахневич, А. Я., Геннадьевна, Х. О., et al. (2023) · doi:10.37539/221216.2022.12.14.006

Faculty Opinions recommendation of Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis.

Madar, Z. (2008) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1102127.558112

97 ADIPOSE TISSUE FAILURE SIGNALS THE EVOLUTION OF HEPATIC STEATOSIS TOWARDS NONALCOHOLIC STEATOHEPATITIS (NASH) IN THE C57BL/6 HFD-INDUCED OBESITY MOUSE MODEL

Duval, C., Boekschoten, M. V., Keshtkar, S., et al. (2008) · Journal of Hepatology · doi:10.1016/s0168-8278(08)60099-9

СТЕАТОЗ І СТЕАТОГЕПАТИТ — ТРИГЕРИ ПЕЧІНКОВОГО ФІБРОГЕНЕЗУ?

Stepanov, Y. М., & Filippova, A. Y. (2013) · GASTROENTEROLOGY · doi:10.22141/2308-2097.2.48.2013.86164 · Cited by 4 · see citing works